GENSIGHT BIOLOGICS SA (SIGHT.PA) Fundamental Analysis & Valuation

EPA:SIGHT • FR0013183985

Current stock price

0.0885 EUR
+0 (+2.08%)
Last:

This SIGHT.PA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. SIGHT.PA Profitability Analysis

1.1 Basic Checks

  • In the past year SIGHT has reported negative net income.
  • SIGHT had a negative operating cash flow in the past year.
  • In the past 5 years SIGHT always reported negative net income.
  • SIGHT had a negative operating cash flow in each of the past 5 years.
SIGHT.PA Yearly Net Income VS EBIT VS OCF VS FCFSIGHT.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -205.69%, SIGHT is doing worse than 91.14% of the companies in the same industry.
Industry RankSector Rank
ROA -205.69%
ROE N/A
ROIC N/A
ROA(3y)-174.59%
ROA(5y)-129.22%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
SIGHT.PA Yearly ROA, ROE, ROICSIGHT.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100 -100 -200

1.3 Margins

  • SIGHT does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SIGHT.PA Yearly Profit, Operating, Gross MarginsSIGHT.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 -1K -2K -3K -4K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

0

2. SIGHT.PA Health Analysis

2.1 Basic Checks

  • SIGHT does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, SIGHT has more shares outstanding
  • The number of shares outstanding for SIGHT has been increased compared to 5 years ago.
  • The debt/assets ratio for SIGHT has been reduced compared to a year ago.
SIGHT.PA Yearly Shares OutstandingSIGHT.PA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
SIGHT.PA Yearly Total Debt VS Total AssetsSIGHT.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

  • SIGHT has an Altman-Z score of -56.53. This is a bad value and indicates that SIGHT is not financially healthy and even has some risk of bankruptcy.
  • SIGHT has a worse Altman-Z score (-56.53) than 89.87% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -56.53
ROIC/WACCN/A
WACC4.95%
SIGHT.PA Yearly LT Debt VS Equity VS FCFSIGHT.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M

2.3 Liquidity

  • A Current Ratio of 0.11 indicates that SIGHT may have some problems paying its short term obligations.
  • SIGHT's Current ratio of 0.11 is on the low side compared to the rest of the industry. SIGHT is outperformed by 96.20% of its industry peers.
  • A Quick Ratio of 0.11 indicates that SIGHT may have some problems paying its short term obligations.
  • SIGHT's Quick ratio of 0.11 is on the low side compared to the rest of the industry. SIGHT is outperformed by 96.20% of its industry peers.
Industry RankSector Rank
Current Ratio 0.11
Quick Ratio 0.11
SIGHT.PA Yearly Current Assets VS Current LiabilitesSIGHT.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. SIGHT.PA Growth Analysis

3.1 Past

  • SIGHT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 78.83%, which is quite impressive.
  • The Revenue for SIGHT has decreased by -91.76% in the past year. This is quite bad
  • The Revenue has been growing by 16.47% on average over the past years. This is quite good.
EPS 1Y (TTM)78.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%23.2%
Revenue 1Y (TTM)-91.76%
Revenue growth 3Y-34.24%
Revenue growth 5Y16.47%
Sales Q2Q%-120.15%

3.2 Future

  • The Earnings Per Share is expected to decrease by -25.99% on average over the next years. This is quite bad
  • The Revenue is expected to grow by 113.86% on average over the next years. This is a very strong growth
EPS Next Y0%
EPS Next 2Y-34.32%
EPS Next 3Y-25.99%
EPS Next 5YN/A
Revenue Next Year-17.42%
Revenue Next 2Y-17.05%
Revenue Next 3Y79.47%
Revenue Next 5Y113.86%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
SIGHT.PA Yearly Revenue VS EstimatesSIGHT.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 20M 40M 60M
SIGHT.PA Yearly EPS VS EstimatesSIGHT.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 -0.2 -0.4 -0.6 -0.8 -1

More info and screens

Find the best growth stocksShow best growing peers

0

4. SIGHT.PA Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for SIGHT. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SIGHT. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SIGHT.PA Price Earnings VS Forward Price EarningsSIGHT.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SIGHT.PA Per share dataSIGHT.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.2 -0.4 -0.6 -0.8

4.3 Compensation for Growth

  • SIGHT's earnings are expected to decrease with -25.99% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-34.32%
EPS Next 3Y-25.99%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. SIGHT.PA Dividend Analysis

5.1 Amount

  • No dividends for SIGHT!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

SIGHT.PA Fundamentals: All Metrics, Ratios and Statistics

GENSIGHT BIOLOGICS SA

EPA:SIGHT (4/2/2026, 7:00:00 PM)

0.0885

+0 (+2.08%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-26
Earnings (Next)04-07
Inst Owners27.73%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap20.80M
Revenue(TTM)194.00K
Net Income(TTM)-15.12M
Analysts80
Price Target0.31 (250.28%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-29.07%
PT rev (3m)-29.07%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-54.79%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-14.29%
Revenue NY rev (3m)-36.17%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 107.22
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.13
EYN/A
EPS(NY)-0.9
Fwd EYN/A
FCF(TTM)-0.03
FCFYN/A
OCF(TTM)-0.03
OCFYN/A
SpS0
BVpS-0.14
TBVpS-0.14
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -205.69%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-174.59%
ROA(5y)-129.22%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.03
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0%
Cap/Sales 0%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.11
Quick Ratio 0.11
Altman-Z -56.53
F-Score3
WACC4.95%
ROIC/WACCN/A
Cap/Depr(3y)8.1%
Cap/Depr(5y)5.68%
Cap/Sales(3y)3.54%
Cap/Sales(5y)2.27%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)78.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%23.2%
EPS Next Y0%
EPS Next 2Y-34.32%
EPS Next 3Y-25.99%
EPS Next 5YN/A
Revenue 1Y (TTM)-91.76%
Revenue growth 3Y-34.24%
Revenue growth 5Y16.47%
Sales Q2Q%-120.15%
Revenue Next Year-17.42%
Revenue Next 2Y-17.05%
Revenue Next 3Y79.47%
Revenue Next 5Y113.86%
EBIT growth 1Y59.36%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year8.62%
EBIT Next 3Y10.85%
EBIT Next 5YN/A
FCF growth 1Y75.87%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y75.8%
OCF growth 3YN/A
OCF growth 5YN/A

GENSIGHT BIOLOGICS SA / SIGHT.PA Fundamental Analysis FAQ

What is the fundamental rating for SIGHT stock?

ChartMill assigns a fundamental rating of 1 / 10 to SIGHT.PA.


What is the valuation status of GENSIGHT BIOLOGICS SA (SIGHT.PA) stock?

ChartMill assigns a valuation rating of 0 / 10 to GENSIGHT BIOLOGICS SA (SIGHT.PA). This can be considered as Overvalued.


Can you provide the profitability details for GENSIGHT BIOLOGICS SA?

GENSIGHT BIOLOGICS SA (SIGHT.PA) has a profitability rating of 0 / 10.


What is the earnings growth outlook for GENSIGHT BIOLOGICS SA?

The Earnings per Share (EPS) of GENSIGHT BIOLOGICS SA (SIGHT.PA) is expected to decline by 0% in the next year.